HomepageMPSYF • OTCMKTS
add
Morphosys
Vorige slotkoers
$ 73,27
Jaar-range
$ 20,15 - $ 73,27
Beurswaarde
2,77 mld. USD
Koers/winst
-
Dividendrendement
-
Marktnieuws
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
| (EUR) | jun 2024info | Wijziging j-o-j |
|---|---|---|
Opbrengst | 34,64 mln. | -34,84% |
Bedrijfskosten | 78,93 mln. | -17,78% |
Netto inkomsten | -79,19 mln. | -7,07% |
Netto winstmarge | -228,59 | -64,30% |
Winst per aandeel | — | — |
EBITDA | -44,38 mln. | 6,70% |
Effectief belastingtarief | — | — |
Balans
Totale activa
Totale passiva
| (EUR) | jun 2024info | Wijziging j-o-j |
|---|---|---|
Contanten en kortetermijnbeleggingen | 512,31 mln. | -23,74% |
Totale activa | 1,71 mld. | -20,42% |
Totale passiva | 2,04 mld. | -3,37% |
Totaal aandelenvermogen | -334,72 mln. | — |
Uitstaande aandelen | 37,66 mln. | — |
Koers-boekwaardeverhouding | -8,24 | — |
Rendement op activa | -6,44% | — |
Rendement op kapitaal | -7,90% | — |
Kasstroom
Nettomutatie in liquide middelen
| (EUR) | jun 2024info | Wijziging j-o-j |
|---|---|---|
Netto inkomsten | -79,19 mln. | -7,07% |
Operationele kasstroom | -131,32 mln. | -4,25% |
Kasstroom uit beleggingen | 116,76 mln. | 402,25% |
Kasstroom uit financiering | -2,98 mln. | 36,22% |
Nettomutatie in liquide middelen | 2,41 mln. | 102,25% |
Vrije kasstroom | 395,49 mln. | 464,18% |
Over
MorphoSys AG is a German biopharmaceutical company founded in 1992. The company is headquartered near Munich, Germany, and has a wholly owned subsidiary, MorphoSys US Inc., in Boston, Massachusetts, in the US. The company has various antibody, protein and peptide technologies that it uses to discover and develop both proprietary and partnered drug candidates. The company has more than 100 drugs in its wider pipeline that are being investigated for a variety of diseases. While many of these are being developed in partnership with pharma and biotech companies, MorphoSys also has a proprietary pipeline with a focus on cancer and autoimmune diseases.
MorphoSys AG was listed on the Frankfurt Stock Exchange and on the US Nasdaq stock exchange. Novartis agreed to acquire the company in February 2024. Wikipedia
Opgericht
1992
Hoofdvestiging
Website
Werknemers
446
